Patents by Inventor Michel Geist

Michel Geist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oncolytic virus for expression of immune checkpoint modulators
    Patent number: 11779619
    Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: October 10, 2023
    Assignee: Transgene SA
    Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
  • ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS
    Publication number: 20200197457
    Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 25, 2020
    Applicant: Transgene S.A.
    Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
  • Oncolytic virus for expression of immune checkpoint modulators
    Patent number: 10555981
    Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 11, 2020
    Assignee: Transgene S.A.
    Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
  • Antibody against the CSF-1R
    Patent number: 9982055
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 29, 2018
    Assignee: TRANSGENE S.A.
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
  • ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS
    Publication number: 20170157188
    Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Applicant: Transgene S.A.
    Inventors: Nathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
  • ANTIBODY AGAINST THE CSF-1R
    Publication number: 20170002081
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 5, 2017
    Inventors: Hélène HAEGEL, Christine Thioudellet, Michel Geist, Benoit Grellier, Jean-Baptiste Marchand
  • Antibody against the CSF-1R
    Patent number: 9428584
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: August 30, 2016
    Assignee: Transgene S.A.
    Inventors: Hèléne Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier, Jean-Baptiste Marchand
  • Antibody against the CSF-1R
    Patent number: 9221912
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: December 29, 2015
    Assignee: Transgene S.A.
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier
  • ANTIBODY AGAINST THE CSF-1R
    Publication number: 20140057972
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Application
    Filed: July 1, 2013
    Publication date: February 27, 2014
    Applicant: TRANSGENE S.A.
    Inventors: Hélène HAEGEL, Christine THIOUDELLET, Michel GEIST, Benoît GRELLIER
  • Antibody against the CSF-1R
    Patent number: 8604170
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: December 10, 2013
    Assignee: Transgene S.A.
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier
  • ANTIBODY AGAINST THE CFR-1R
    Publication number: 20130289250
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Application
    Filed: May 17, 2013
    Publication date: October 31, 2013
    Applicant: TRANSGENE, S.A.
    Inventors: Helene HAEGEL, Christine THIOUDELLET, Michel GEIST, Benoit GRELLIER, Jean-Baptiste MARCHAND
  • Antibody against the CSF-1R
    Patent number: 8470977
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: June 25, 2013
    Assignee: Transgene S.A.
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier, Jean-Baptiste Marchand
  • Antibody Against the CSF-1R
    Publication number: 20110178278
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Application
    Filed: February 14, 2011
    Publication date: July 21, 2011
    Inventors: Hélène HAEGEL, Christine Thioudellet, Michel Geist, Benoît Grellier, Jean-Baptiste Marchand
  • ANTIBODY AGAINST THE CSF-1 R
    Publication number: 20110081353
    Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.
    Type: Application
    Filed: March 11, 2009
    Publication date: April 7, 2011
    Inventors: Hélène Haegel, Christine Thioudellet, Michel Geist, Benoît Grellier
  • Poxvirus with targeted infection specificity
    Patent number: 7354591
    Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 8, 2008
    Assignee: Transgene S.A.
    Inventors: Jean-Marc Balloul, Stéphane Paul, Michel Geist
  • Poxvirus with targeted infection specificity
    Patent number: 7348014
    Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: March 25, 2008
    Assignee: Transgene, S.A.
    Inventors: Jean Marc Balloul, Stephane Paul, Michel Geist, Nathalle Silvestre, Philippe Erbs
  • Poxvirus with targeted infection specificity
    Publication number: 20050208074
    Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes.
    Type: Application
    Filed: September 7, 2004
    Publication date: September 22, 2005
    Applicant: TRANSGENE S.A.
    Inventors: Jean Balloul, Stephane Paul, Michel Geist, Nathalle Silvestre, Philippe Erbs
  • Poxvirus with targeted infection specificity
    Publication number: 20030165477
    Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
    Type: Application
    Filed: April 12, 2001
    Publication date: September 4, 2003
    Inventors: Jean-Marc Balloul, Stephane Paul, Michel Geist